美股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

Invesco Nasdaq Biotechnology ETF

34.78

-0.3458-0.98%

成交量：2.24萬

成交額：77.84萬

市值：9,668.84萬

市盈率：- -

高：35.13

開：35.13

低：34.63

收：35.13

52周最高：36.84

52周最低：23.42

股本：278.00萬

流通股本：278.00萬

量比：1.07

換手率：0.81%

股息：0.26

股息率：0.74%

淨資產收益率：--

總資產收益率：--

市淨率：--

市盈率(LYR):- -

資料載入中...

總覽公司新聞資訊公告

我國創新藥出海再提速今年對外授權突破1200億美元

智通港股解盤 | 美國放緩AI另有玄機 WCLC大會再度催化創新藥

縮量震盪下，創新藥逆市爆發，中證銀行指數上探年內新高！光模塊回調，高「光」ETF獲資金逢低關注

博安生物：BA1203獲准開展臨床試驗

南方财经网

ETF日報：短期看在A股整體市場動能偏弱、熱點輪動加快的環境下，前期調整的創新藥、CXO板塊擁有一定性價比

康哲藥業(00867)：創新藥高選擇性TYK2抑制劑CMS-D001 獲得系統性紅斑狼瘡適應症藥物臨床試驗批准通知書

康哲藥業：9月14日CMS-D001獲SLE臨床試驗批准

恒瑞創新藥凝血因子XI單抗SHR-2004注射液用於擇期膝關節置換手術後成年患者靜脈血栓預防的上市申請獲受理

白雲山：超10個創新藥管線引進項目已完成立項

ETF日報(09.14)丨WCLC臨床數據密集兑現，創新藥板塊震盪回升算力需求預期遭重估

阿斯利康(AZN.US)乳腺癌藥物Etcamah三期臨床試驗受挫或致數十億美元銷售額蒙陰

阿斯利康(AZN.US)乳腺癌藥物Etcamah三期臨床試驗受挫或致數十億美元銷售額蒙陰

ETF異動 | 華夏恒生生科(03069)升逾4% WCLC臨床數據催化密集機構看好創新藥投資機會

【券商聚焦】華創證券維持翰森製藥（03692）推薦評級指創新藥驅動業績增長

A股收評：創業板指震盪走低跌1.1%，培育鑽石、創新藥、MLCC概念板塊漲幅居前

創新藥闖關醫保

国际金融报

港股異動 | 科倫博泰生物(06990)升逾3% POLARIS-1臨床試驗2期部分取得陽性結果並已啓動3期臨床

港股異動 | 創新藥概念股全線走高 WCLC臨床數據重磅催化機構指回調後配置價值凸顯

A股午評：滬指低開高走漲0.16%，MLCC概念、創新藥、培育鑽石板塊表現活躍

長風藥業（02652）續漲3.76% ICF001拿到三項臨床試驗默示許可

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/hant/stock/IBBQ/news?page=5"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"IBBQ","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"IBBQ\",,,,,undefined,":{"symbol":"IBBQ","market":"US","secType":"STK","nameCN":"Invesco Nasdaq Biotechnology ETF","latestPrice":34.78,"timestamp":1789760027691,"preClose":35.1258,"halted":0,"volume":22404,"delay":0,"changeRate":-0.00984461563864729,"floatShares":2780001,"shares":2780001,"eps":0,"marketStatus":"交易中","change":-0.3458,"latestTime":"09-18 15:34:51 EDT","open":35.13,"high":35.13,"low":34.6296,"amount":778391.4920640001,"amplitude":0.014246,"askPrice":34.74,"askSize":1200,"bidPrice":34.7,"bidSize":600,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":2,"nextMarketStatus":{"tag":"盤後交易","tradingStatus":3,"beginTime":1789761600000},"marketStatusCode":2,"adr":0,"exchange":"NASDAQ","adjPreClose":35.1258,"sharesOutstanding":2520001,"nav":34.34966,"aum":95492089.14966,"dividendRate":0.007386,"bidAskSpread":0,"postHourTrading":{"tag":"盘后","latestPrice":35.14,"preClose":35.1258,"latestTime":"19:58 EDT","volume":117,"amount":4061.8054,"timestamp":1789689522745,"change":0.0142,"changeRate":0.000404,"amplitude":0},"volumeRatio":1.070222,"impliedVol":0.0455,"impliedVolPercentile":0.0199},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"IBBQ\",,,,,undefined,":{"symbol":"IBBQ","floatShares":2780001,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":1.070222,"shares":2780001,"dividePrice":0.2569,"high":35.13,"amplitude":0.014246,"preClose":35.1258,"low":34.6296,"week52Low":23.42,"pbRate":"--","week52High":36.84,"institutionHeld":0,"latestPrice":34.78,"committee":-0.333333,"eps":0,"divideRate":0.007386,"volume":22404,"delay":0,"ttmEps":0,"open":35.13,"prevYearClose":28.3962,"prevWeekClose":34.472,"prevMonthClose":35.4742,"prevQuarterClose":32.66,"fiveDayClose":34.472,"twentyDayClose":35.8,"sixtyDayClose":31.2119},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/IBBQ\",params:#limit:5,,,undefined,":[{"date":"2026-06-22","symbol":"IBBQ","amount":0.03422,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-06-22","defaultRemindTime":1782135000000,"name":"Invesco Nasdaq Biotechnology ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-06-26","payableDate":"2026-06-22","currency":"USD","dateTimestamp":1782100800000,"payDate":"2026-06-26"},{"date":"2026-03-23","symbol":"IBBQ","amount":0.03609,"announcedDate":"2026-03-20","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-03-23","defaultRemindTime":1774272600000,"name":"Invesco Nasdaq Biotechnology ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-03-27","payableDate":"2026-03-23","currency":"USD","dateTimestamp":1774238400000,"payDate":"2026-03-27"},{"date":"2025-12-22","symbol":"IBBQ","amount":0.0906,"announcedDate":"2025-12-19","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-12-22","defaultRemindTime":1766413800000,"name":"Invesco Nasdaq Biotechnology ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-12-26","payableDate":"2025-12-22","currency":"USD","dateTimestamp":1766379600000,"payDate":"2025-12-26"},{"date":"2025-09-22","symbol":"IBBQ","amount":0.09576,"announcedDate":"2025-09-19","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-09-22","defaultRemindTime":1758547800000,"name":"Invesco Nasdaq Biotechnology ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-09-26","payableDate":"2025-09-22","currency":"USD","dateTimestamp":1758513600000,"payDate":"2025-09-26"},{"date":"2025-06-23","symbol":"IBBQ","amount":0.0287,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-06-23","defaultRemindTime":1750685400000,"name":"Invesco Nasdaq Biotechnology ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-06-27","payableDate":"2025-06-23","currency":"USD","dateTimestamp":1750651200000,"payDate":"2025-06-27"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"IBBQ\",market:\"US\",,,undefined,":[{"executeDate":"2021-09-20","recordDate":"2021-09-21","paymentDate":"2021-09-30","value":0.04324,"currency":"USD"},{"executeDate":"2021-12-20","recordDate":"2021-12-21","paymentDate":"2021-12-31","value":0.10511,"currency":"USD"},{"executeDate":"2022-03-21","recordDate":"2022-03-22","paymentDate":"2022-03-31","value":0.03778,"currency":"USD"},{"executeDate":"2022-06-21","recordDate":"2022-06-22","paymentDate":"2022-06-30","value":0.04264,"currency":"USD"},{"executeDate":"2022-09-19","recordDate":"2022-09-20","paymentDate":"2022-09-23","value":0.03769,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"IBBQ\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"IBBQ\",pageSize:20,pageCount:5,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2667886669","title":"我國創新藥出海再提速 今年對外授權突破1200億美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2667886669","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667886669?lang=zh_tw&edition=fundamental","pubTime":"2026-09-14 20:58","pubTimestamp":1789390730,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["MEDX","IBBQ","LNGR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667666143","title":"智通港股解盤 | 美國放緩AI另有玄機 WCLC大會再度催化創新藥","url":"https://stock-news.laohu8.com/highlight/detail?id=2667666143","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667666143?lang=zh_tw&edition=fundamental","pubTime":"2026-09-14 20:45","pubTimestamp":1789389921,"startTime":"0","endTime":"0","summary":"科技股的走弱，和 Anthropic、OpenAI 与 SpaceX 罕见联手集体呼吁放缓AI 开发步伐有关。业绩方面，多光谱 AI 大模型服务收入冲到 3.20 亿元，同比暴涨 382.5%，收入占比直接从 29.8% 飙升至 78%。机构认为，2026 年 WCLC 大会的主角仍是 IO2.0 与 ADC，肺癌领域尤其是 1L 非小细胞肺癌的标准治疗范式正处于迭代前夜，国产双抗与 ADC 的进度全球领先。授权品种的里程碑付款与商业化分成，正在成为创新药企业价值兑现的第二曲线。这是公司首款双抗 ADC 获批临床，也是公司第三款 ADC 创新药进入临床。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1495830.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1521","00135","LU0593848301.USD","LU1515016050.SGD","BK1161","IBBQ","MEDX","LU1969619763.USD","AGIX","LU0307460666.USD","CHAT","IE0034224299.USD","QTOC","VTHR","LNGR","06690","KCAI","BK1500","LU0651946864.USD","IE00BZ08YR35.GBP","06978","LU1808992512.USD","02688","BK1566","IE00BGHQDM52.EUR","IE00BPRC5H50.USD","IE00BZ08YT58.USD","KURE","LU0640798160.USD","LU0877626530.USD","09969","LU0821914370.USD","IE0008369823.USD","IE00B543WZ88.USD","IE00B29SXG58.USD","LU0431992006.USD","LU1051768304.USD","01193","LU0348735423.USD","BK4588","LU1224709979.USD","06160","IE00BMCWC346.EUR","159992","VXUS","ARTY","BK1574","LU0287142896.SGD","IE00BZ08YS42.EUR","AIPO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667668966","title":"縮量震盪下，創新藥逆市爆發，中證銀行指數上探年內新高！光模塊回調，高「光」ETF獲資金逢低關注","url":"https://stock-news.laohu8.com/highlight/detail?id=2667668966","media":"新浪基金","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667668966?lang=zh_tw&edition=fundamental","pubTime":"2026-09-14 19:10","pubTimestamp":1789384200,"startTime":"0","endTime":"0","summary":"AI硬件赛道普遍回调，受硅谷“降速”言论影响，光模块龙头承压明显，高“光”创业板人工智能ETF华宝标的指数收跌2%，资金逢低关注布局机会。分红方面，国有六大行2026年度中期现金分红总额拟超2000亿元，同时为进一步增强投资者的获得感，均将中期拟分红比例由30%提高至31%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/money/fund/etf/2026-09-14/doc-iniruxuu7290017.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["FDN","159992","399986","LYTE","BK1574","AAOG","159253","BK4550","LUMA","BK4585","MEDX","BK1161","LNGR","BK4588","AAOX","06978","IBBQ","AAOZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667668638","title":"博安生物：BA1203獲准開展臨床試驗","url":"https://stock-news.laohu8.com/highlight/detail?id=2667668638","media":"南方财经网","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667668638?lang=zh_tw&edition=fundamental","pubTime":"2026-09-14 19:04","pubTimestamp":1789383840,"startTime":"0","endTime":"0","summary":"南财智讯9月14日电，博安生物（06955.HK）发布自愿公告，公司自主研发的在研PD-1/IL-2抗体细胞因子前药BA1203的新药临床试验申请（IND）已获得中国国家药品监督管理局药品审评中心（CDE）批准，拟开发用于多种实体瘤的治疗。BA1203为全球唯一的IL-2α受体高活性、遮蔽型且PD-1阻断型PD-1/IL-2分子。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202609143873558977.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202609143873558977.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["06955","IBBJ","PSYK","IBBQ","BMED","BK1161","MDTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667685646","title":"ETF日報：短期看在A股整體市場動能偏弱、熱點輪動加快的環境下，前期調整的創新藥、CXO板塊擁有一定性價比","url":"https://stock-news.laohu8.com/highlight/detail?id=2667685646","media":"新浪基金","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667685646?lang=zh_tw&edition=fundamental","pubTime":"2026-09-14 19:02","pubTimestamp":1789383720,"startTime":"0","endTime":"0","summary":"形成赛道级利好共振，重塑市场对创新药研发进度与商业化价值的预期，修复创新药β行情，抬升CXO产业链订单与研发景气度预期。前期创新药、CXO板块经历持续回调，整体估值与市场情绪充分降温，板块点位回落至6-8月宽幅震荡箱体下沿位置，具备一定的技术性反弹空间。展望后市，短期看，在A股整体市场动能偏弱、热点轮动加快、反弹逐步收敛的环境下，前期调整的创新药、CXO板块拥有一定性价比。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/money/fund/etf/2026-09-14/doc-iniruxuw4057482.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["CXO","159992","02846","06978","BK1161","BK1574","03188","MEDX","LNGR","83188","83130","399300","02827","159982","FDN","IBBQ","82846","BK1147","BK4588","BK4585","WX","03130","BK4550","07233"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667657414","title":"康哲藥業(00867)：創新藥高選擇性TYK2抑制劑CMS-D001 獲得系統性紅斑狼瘡適應症藥物臨床試驗批准通知書","url":"https://stock-news.laohu8.com/highlight/detail?id=2667657414","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667657414?lang=zh_tw&edition=fundamental","pubTime":"2026-09-14 18:23","pubTimestamp":1789381419,"startTime":"0","endTime":"0","summary":"智通财经APP讯，康哲药业 公布，于2026年9月11日，创新药CMS-D001片获得中国国家药品监督管理局签发的药物临床试验批准通知书，于2026年9月14日收到药物临床试验批准通知书。NMPA同意集团开展临床试验以评价CMS-D001治疗系统性红斑狼疮适应症的有效性和安全性。CMS-D001作为高选择性TYK2抑制剂，相较于泛JAK抑制剂，CMS-D001对其他JAK家族激酶的影响较小，可在长期疾病控制中维持疗效并降低相关安全风险。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1495742.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["SG9999015952.SGD","SG9999004220.SGD","MDTX","BK1574","SG9999015978.USD","IE00BYV24P56.USD","PSYK","159992","IE00BMCWC346.EUR","BK1161","LNGR","SG9999015986.USD","SG9999004311.SGD","LU2488822045.USD","IE00BVYPNP33.GBP","IE00BGHQDM52.EUR","BMED","IBBQ","IE00BVYPNQ40.USD","BK1191","00867","SG9999015945.SGD","06978","BK1593","MEDX","IBBJ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667657480","title":"康哲藥業：9月14日CMS-D001獲SLE臨床試驗批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2667657480","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667657480?lang=zh_tw&edition=fundamental","pubTime":"2026-09-14 18:23","pubTimestamp":1789381383,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["IBBJ","SLE","MDTX","IBBQ","PSYK","BMED","BK4077"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667657738","title":"恒瑞創新藥凝血因子XI單抗SHR-2004注射液用於擇期膝關節置換手術後成年患者靜脈血栓預防的上市申請獲受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2667657738","media":"恒瑞医药","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667657738?lang=zh_tw&edition=fundamental","pubTime":"2026-09-14 17:59","pubTimestamp":1789379940,"startTime":"0","endTime":"0","summary":"近日，恒瑞医药子公司北京盛迪医药有限公司收到国家药监局下发的《受理通知书》，公司1类创新药、凝血因子XI单克隆抗体SHR-2004注射液的药品上市许可申请获受理，拟定适应症为：用于择期膝关节置换手术的成年患者，以预防静脉血栓形成。该研究旨在评价行择期TKA的患者使用SHR-2004注射液预防静脉血栓栓塞症的有效性和安全性。此外，SHR-2004用于卵巢癌术后VTE预防的Ⅱ期试验已完成。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2026-09-14/doc-iniruxuy4531842.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["MEDX","159992","IBBQ","06978","IPOS","BK1574","LNGR","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667654298","title":"白雲山：超10個創新藥管線引進項目已完成立項","url":"https://stock-news.laohu8.com/highlight/detail?id=2667654298","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667654298?lang=zh_tw&edition=fundamental","pubTime":"2026-09-14 17:36","pubTimestamp":1789378605,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["MEDX","LNGR","IBBQ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667582651","title":"ETF日報(09.14)丨WCLC臨床數據密集兑現，創新藥板塊震盪回升 算力需求預期遭重估","url":"https://stock-news.laohu8.com/highlight/detail?id=2667582651","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667582651?lang=zh_tw&edition=fundamental","pubTime":"2026-09-14 16:44","pubTimestamp":1789375451,"startTime":"0","endTime":"0","summary":"WCLC临床数据密集兑现，创新药板块震荡回升；AI巨头集体\"喊停\"，算力需求预期遭重估，通信板块多数走低。行业表现WCLC临床数据密集兑现，国内外投行相继看好中国CRO/CDMO复苏明确，创新药板块震荡回升。消息面上，9月12日至15日，2026年世界肺癌大会在韩国首尔举行，多项国产创新药临床数据集中亮相，中国新药入选口头报告19项、小型口头报告45项，双双刷新历史纪录，肺癌领域ADC与双抗数据成为焦点。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1495613.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["06978","AIVC","BK4588","LNGR","159992","BK1574","AIQD","BK4585","FDN","IBBQ","EPAI","MEDX","AIQU","BAI","BK1161","BK4550"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667599986","title":"阿斯利康(AZN.US)乳腺癌藥物Etcamah三期臨床試驗受挫 或致數十億美元銷售額蒙陰","url":"https://stock-news.laohu8.com/highlight/detail?id=2667599986","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667599986?lang=zh_tw&edition=fundamental","pubTime":"2026-09-14 16:27","pubTimestamp":1789374476,"startTime":"0","endTime":"0","summary":"Bloomberg Intelligence分析师John Murphy表示，阿斯利康此次乳腺癌药物试验受挫可能使2035年的销售额减少26亿至38亿美元。ESR1突变是ER阳性乳腺癌内分泌治疗耐药的重要机制。CAMBRIA-1比较Etcamah延长辅助治疗5年 vs 标准内分泌治疗，中高复发风险。如果CAMBRIA阳性，Etcamah的市场空间将远大于晚期ESR1突变人群——这也是阿斯利康对Etcamah 50亿美元峰值销售额预期的核心支撑。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1495608.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BMED","IBBJ","PSYK","IBBQ","MDTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667599576","title":"阿斯利康(AZN.US)乳腺癌藥物Etcamah三期臨床試驗受挫 或致數十億美元銷售額蒙陰","url":"https://stock-news.laohu8.com/highlight/detail?id=2667599576","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667599576?lang=zh_tw&edition=fundamental","pubTime":"2026-09-14 16:27","pubTimestamp":1789374476,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["PSYK","BMED","IBBJ","IBBQ","MDTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667554366","title":"ETF異動 | 華夏恒生生科(03069)升逾4% WCLC臨床數據催化密集 機構看好創新藥投資機會","url":"https://stock-news.laohu8.com/highlight/detail?id=2667554366","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667554366?lang=zh_tw&edition=fundamental","pubTime":"2026-09-14 15:17","pubTimestamp":1789370250,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，华夏恒生生科涨超4%。截至发稿，涨4.01%，报15.58港元，成交额6924.78万港元。本次WCLC会议上，中国新药表现亮眼，入选口头报告研究19项，小型口头报告研究45项，刷新记录。国金证券称，创新药企业扭亏节点到来，全年临床数据催化密集，叠加已BD出海管线海外临床进展顺利，看好创新药板块投资机会。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1495572.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4588","06978","LNGR","BK4550","BK1161","03069","MEDX","FDN","BK1574","BK4585","IBBQ","159992"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667655868","title":"【券商聚焦】華創證券維持翰森製藥（03692）推薦評級 指創新藥驅動業績增長","url":"https://stock-news.laohu8.com/highlight/detail?id=2667655868","media":"金吾财讯","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667655868?lang=zh_tw&edition=fundamental","pubTime":"2026-09-14 15:01","pubTimestamp":1789369287,"startTime":"0","endTime":"0","summary":"金吾财讯 | 华创证券发布研报指，翰森制药 2026年上半年实现总营业收入83.04亿元人民币，创新药收入约70.92亿元，占总收入比例约85.4%创历史新高；净利润42.58亿元。研发管线方面，公司创新药临床试验超70项，候选创新药超40个。华创证券指，公司创新药收入驱动业绩稳健增长，BD出海持续推进，在研管线储备丰富，看好聚焦创新和国际化的战略布局。预计2026-2028年营收分别为165.12/185.22/209.34亿元人民币，同比增长9.9%/12.2%/13.0%；归母净利润为61.10/67.78/75.09亿元人民币。","market":"hk","thumbnail":"https://static.szfiu.com/news/20250109/MjdmY2Y4OTEwODUyNTc5NjI3Mg==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/MjdmY2Y4OTEwODUyNTc5NjI3Mg==.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1991502","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06978","161027","03692","KCE","MEDX","IBBQ","LNGR","159992"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667534816","title":"A股收評：創業板指震盪走低跌1.1%，培育鑽石、創新藥、MLCC概念板塊漲幅居前","url":"https://stock-news.laohu8.com/highlight/detail?id=2667534816","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667534816?lang=zh_tw&edition=fundamental","pubTime":"2026-09-14 15:01","pubTimestamp":1789369262,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["IBBQ","MLCC","MEDX","LNGR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667653941","title":"創新藥闖關醫保","url":"https://stock-news.laohu8.com/highlight/detail?id=2667653941","media":"国际金融报","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667653941?lang=zh_tw&edition=fundamental","pubTime":"2026-09-14 14:46","pubTimestamp":1789368365,"startTime":"0","endTime":"0","summary":"张力制图9月5日至8日，2026年国家基本医保药品目录现场谈判（下称“国谈”）竞价工作在北京开展，上百家国内外药企代表到场参与。本次共有124个目录外药品入围谈判竞价环节，肿瘤、罕见病、慢性病、儿童用药等社会关注度较高的创新药均在列，有望通过谈判纳入新版国家医保目录。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202609143873368645.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202609143873368645.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["IBBQ","06978","BK1161","MEDX","159992","BK1574","LNGR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667658010","title":"港股異動 | 科倫博泰生物(06990)升逾3% POLARIS-1臨床試驗2期部分取得陽性結果 並已啓動3期臨床","url":"https://stock-news.laohu8.com/highlight/detail?id=2667658010","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667658010?lang=zh_tw&edition=fundamental","pubTime":"2026-09-14 14:36","pubTimestamp":1789367775,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，科伦博泰生物涨超3%，截至发稿，涨3.35%，报480.8港元，成交额2.53亿港元。消息面上，近日，科伦博泰生物发布公告，公司的合作方Windward Bio AG已公布SKB378/WIN378用于治疗哮喘的POLARIS-1临床试验2期部分取得阳性的中期结果。POLARIS-1的3期部分已由Windward Bio启动，确定采用两种每年两次给药的剂量方案，旨在评估SKB378/WIN378对重度哮喘患者的年化哮喘急性发作率及其他关键疗效指标的影响。POLARIS-1的2期研究数据将在即将召开的医学会议上公布。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1495550.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["VXUS","BK4588","BK4585","IBBJ","LU0196878994.USD","KCAI","MDTX","06990","IBBQ","PSYK","BK1161","BMED"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667608630","title":"港股異動 | 創新藥概念股全線走高 WCLC臨床數據重磅催化 機構指回調後配置價值凸顯","url":"https://stock-news.laohu8.com/highlight/detail?id=2667608630","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667608630?lang=zh_tw&edition=fundamental","pubTime":"2026-09-14 13:39","pubTimestamp":1789364389,"startTime":"0","endTime":"0","summary":"消息面上，9月12-15日，2026年世界肺癌大会召开，多项中国创新药临床数据集中亮相，康方生物依沃西单药OS数据、B7H3ADC等成为焦点。中泰证券指出，WCLC集中披露的多项肺癌领域临床进展，进一步验证了中国创新药的临床价值和全球竞争力，或可积极把握创新药回调后的配置机会。机构普遍认为，三季度部分企业新增订单进入收入确认期，基本面有望持续改善。当前医药板块估值27倍PE，低于历史均值，回调后配置价值凸显。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1495523.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0634319403.HKD","LU0348784397.USD","LU0348767384.USD","09969","LU2488822045.USD","LU0348735423.USD","LU1188198961.HKD","BK1593","LU0455707207.USD","LU2097828557.USD","LU0607220059.USD","IE00BZ08YR35.GBP","01801","LU0348827113.USD","BK1521","MEDX","LU2097828714.EUR","LU0348766576.USD","LU0417516571.SGD","LU1831875114.USD","IE00B543WZ88.USD","LU2242644610.SGD","LU2778985437.USD","LU2476274720.SGD","LU1969619763.USD","LU2476274308.USD","KCAI","01530","LU0417516738.SGD","LU0326950275.SGD","IE00BPRC5H50.USD","LU0561508036.HKD","HK0000165453.HKD","LU0348825331.USD","159992","LNGR","BK1589","LU2097828805.USD","01177","IBBQ","BK1574","09926","LU0244354667.USD","KURE","LU1961090484.USD","VXUS","06978","BK1191","BK4588","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667632818","title":"A股午評：滬指低開高走漲0.16%，MLCC概念、創新藥、培育鑽石板塊表現活躍","url":"https://stock-news.laohu8.com/highlight/detail?id=2667632818","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667632818?lang=zh_tw&edition=fundamental","pubTime":"2026-09-14 11:31","pubTimestamp":1789356669,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["MEDX","LNGR","IBBQ","MLCC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667631770","title":"長風藥業（02652）續漲3.76% ICF001拿到三項臨床試驗默示許可","url":"https://stock-news.laohu8.com/highlight/detail?id=2667631770","media":"金吾财讯","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667631770?lang=zh_tw&edition=fundamental","pubTime":"2026-09-14 10:16","pubTimestamp":1789352216,"startTime":"0","endTime":"0","summary":"金吾财讯 | 长风药业（02652）股价扬升，续涨3.76%，报10.75港元，成交额3166万港元。消息面上，长风药业自研创新药长效吸入粉雾剂ICF001接连拿到三项临床试验默示许可。截至目前，这款候选药物已覆盖PAH、PH-ILD、IPF、PPF四大适应症，也是国内首家将该类长效吸入前药推进至国内临床试验阶段的企业。公司董事长兼执行董事梁文青博士称，将同步开展海内外I期临床，积极布局海外合作开发、区域授权等全球化商业化路径。","market":"sh","thumbnail":"https://static.szfiu.com/news/20241108/OTEzM2QyMzQzMjc2MzA3OTk2MA==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/OTEzM2QyMzQzMjc2MzA3OTk2MA==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1991472","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1191","IBBJ","MDTX","BMED","IBBQ","02652","PSYK"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":11,"pageCount":5,"totalSize":219,"code":"91000000","status":"200"}]}}